Crofelemer regulatory update

Salix submitted an NDA to FDA for crofelemer to treat HIV-associated diarrhea. The submission comes just a month after Napo said it terminated a 2008 deal that gave Salix rights to crofelemer in North America,

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE